Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
The following are inclusion criteria for each patient cohort:
- Females age 18 and above.
- Any subtype of breast cancer (HER2+, ER/PR, TNBC, BRCA1 +/-, other).
Patient Cohort:
Biopsy negative
- Females age 18 and above.
Biopsy positive for carcinoma in situ (ductal, lobular, or other)
- Females age 18 and above.
- Any subtype of breast cancer..
Biopsy positive for Stage 1, 2, or 3 invasive carcinoma (ductal, lobular, or other)
- Females age 18 and above.
- Any subtype of breast cancer.
- Have no distant metastases.
Stage 4 metastatic disease
- Females age 18 and above.
- Any subtype of breast cancer.
Exclusion Criteria:
For all cohorts exclusion criteria includes:
- Males.
- Any subject less than 18 years of age.
- Previous diagnosis with a known platelet disorder.
Patient Cohort:
Biopsy negative
- Males.
- Females less than age 18.
Biopsy positive for carcinoma in situ (ductal, lobular, or other)
- Males.
- Females less than age 18.
- Currently undergoing neoadjuvant therapy.
Biopsy positive for Stage 1, 2, or 3 invasive carcinoma (ductal, lobular, or other)
- Males
- Females less than age 18.
- Presence of distant metastases.
- Currently undergoing neoadjuvant therapy.
Stage 4 metastatic disease
- Males.
- Females less than age 18.
- Currently undergoing neoadjuvant therapy.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Eligibility last updated 6/1/23. Questions regarding updates should be directed to the study team contact.